Distinguished Oncologist and Cancer Data Researcher, Dr. Amy Abernethy, Joins Flatiron Health as Chief Medical Officer and SVP of Oncology
Flatiron Health is announcing the appointment of Amy Abernethy, MD, PhD, as the new chief medical officer and senior vice president of oncology. Dr. Abernethy is an internationally recognized oncologist and cancer researcher from Duke University and the co-director of both the Duke Center for Learning Health Care and the Duke Cancer Care Research Program. For more than a decade, she has pioneered the development of technology platforms to spur novel advancements in cancer care, including the development of systems by which big data can support personalized medicine and scientific discovery.
Dr. Abernethy will help direct Flatiron Health through the next phase of the company’s growth. Flatiron Health aims to improve cancer care by organizing the world’s real-world oncology data and making it useful for patients, physicians and researchers. Dr. Abernethy’s expertise will support the practical implementation of personalized cancer care by helping Flatiron Health provide the data that enables the right patient to get the right therapy at the right time.
“We are at a critical crossroads in cancer care,” said Dr. Abernethy. “Cancer data science has the potential to improve the lives of countless patients and families. But we still need to develop the strategic and operational pathways. Flatiron Health has the vision and ingenuity needed to revolutionize cancer care and I’m excited to be a member of the team working to solve this puzzle.”
“Being able to recruit one of the industry’s top cancer physicians and cancer data scientists, who is also a major proponent of patient-centered care, is a huge boost to Flatiron Health’s efforts,” said Nat Turner, Flatiron Health’s co-founder. “Dr. Abernethy’s hire, along with our recent successful funding round and acquisition of Altos Solutions, will help Flatiron Health move quickly to address the data opportunity in cancer.”
At Flatiron Health, Dr. Abernethy will collaborate with cancer care providers, life science companies and data partners to solve practical data and analytic problems. She will lead the clinical and oncology data teams, and contribute to the strategic vision of Flatiron Health. Dr. Abernethy will be on a leave of absence from the majority of her responsibilities at Duke University in order to advance this mission.
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth